Anbogen Therapeutics
- Biotech or pharma, therapeutic R&D
AnBogen Therapeutics is a clinical-stage biotechnology company dedicated to developing precision oncology therapies to improve patients' lives.
At the upcoming BIO International Convention in June, AnBogen aims to engage in out-licensing and co-development partnerships to accelerate the global development of its lead assets. The pipeline includes:
- ABT-301: A novel oral epigenetic modulator designed to enhance immune checkpoint blockade. Preclinical studies have demonstrated that ABT-301 modulates the tumor microenvironment, increasing CD8+ T-cell infiltration and reducing immunosuppressive cells, thereby potentiating the efficacy of anti-PD-1 therapies. ABT-301 is currently being evaluated in a global Phase II trial in combination with BeiGene’s tislelizumab for mCRC.
- ABT-501: An innovative peptide-drug conjugate (PDC) that combines a novel linker-DM1 release functional group with luteinizing hormone-releasing hormone (LHRH) to TNBC, ovarian cancers and prostate cancer.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}